Edwards Lifesciences Corporation Q3 2026 Earnings Recap

Edwards rose 1.5% after reporting third-quarter sales growth of 11.2% and raising full-year sales and adjusted EPS guidance. The move was within ±3%, so the reaction was relatively muted despite management’s positive characterization of the quarter.

Key Takeaways

• Third-quarter sales were $1.72 billion, up 11.2%; management said both businesses and regions contributed to performance.
• TAVR sales were $1.2 billion, up 8.8% year over year, with growth rates similar in the U.S. and internationally; average selling prices were stable globally.
• The company raised full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97–$3.05.
• Management cited recent clinical, regulatory and product developments as opportunities for longer-term growth, while describing their impact as multiyear and expected to build over time.
• Edwards reiterated a long-term target of approximately 10% average annual sales growth alongside leveraged EPS growth.